Cargando…

Quantification of the myocardial partition coefficient for intravenous iron (ferric carboxymaltose) using T1 mapping cardiovascular magnetic resonance

Detalles Bibliográficos
Autores principales:	Abdula, Goran, Valadkhani, Arman, Lundin, Magnus, Sörensson, Peder, Sigfridsson, Andreas, Ugander, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032793/ http://dx.doi.org/10.1186/1532-429X-18-S1-P229

Ejemplares similares

Native myocardial T1 precision is increased by correcting for myocardial blood variation
por: Nickander, Jannike, et al.
Publicado: (2015)

Synthetic phase sensitive inversion recovery late gadolinium enhancement from post-contrast T1-mapping shows excellent agreement with conventional PSIR-LGE for diagnosing myocardial scar
por: Abdula, Goran, et al.
Publicado: (2014)

Blood correction reduces variability and gender differences in native myocardial T1 values at 1.5 T cardiovascular magnetic resonance – a derivation/validation approach
por: Nickander, Jannike, et al.
Publicado: (2017)

Stationary tissue background correction increases the precision of clinical evaluation of intra-cardiac shunts by cardiovascular magnetic resonance
por: Nickander, Jannike, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Measurement of the intracellular lifetime of water to estimate myocardial cell size is not feasible in humans using clinical contrast agent doses at 1.5T
por: Lundin, Magnus, et al.
Publicado: (2016)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
por: Cancado, Rodolfo Delfini, et al.
Publicado: (2020)

In patients with acute myocarditis, the difference in apparent extracellular volume fraction between affected and healthy myocardium does not differ between early and late post-contrast imaging
por: Lundin, Magnus, et al.
Publicado: (2016)

Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
por: Kanshaiym, Sakiyeva, et al.
Publicado: (2020)

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)

A semi-automatic method for quantification of respiratory variation in early mitral inflow velocity using real time phase contrast cardiac magnetic resonance - normal values and clinical feasibility
por: Thalén, Simon, et al.
Publicado: (2016)

Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
por: Korczowski, Bartosz, et al.
Publicado: (2023)

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
por: Fang, Wendy, et al.
Publicado: (2019)

Background phase correction in phase contrast velocity encoded CMR reduces gender differences and improves the accuracy and precision of Qp/Qs
por: Nickander, Jannike, et al.
Publicado: (2015)

Cost-Minimization Analysis Favours Intravenous Ferric Carboxymaltose over Ferric Sucrose for the Ambulatory Treatment of Severe Iron Deficiency
por: Calvet, Xavier, et al.
Publicado: (2012)

Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review
por: Aksan, Aysegül, et al.
Publicado: (2022)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Treatment of Iron Deficiency With Intravenous Ferric Carboxymaltose in General Practice: A Retrospective Database Study
por: Kuster, Martina, et al.
Publicado: (2015)

Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
por: Bourguignon, Sandrine, et al.
Publicado: (2019)

MON-338 Severe Hypophosphatemia Induced by Intravenous Ferric Carboxymaltose Therapy for Iron Deficiency Anemia
por: Tam, Matthew, et al.
Publicado: (2020)

Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
por: Theidel, Ulrike, et al.
Publicado: (2017)

Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia
por: Basha, Ahmad, et al.
Publicado: (2021)

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
por: Adkinson, N. Franklin, et al.
Publicado: (2018)

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency(†)
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

Extracellular volume MRI increases the detection of myocardial abnormalities beyond late gadolinium enhancement - initial findings
por: Lundin, Magnus, et al.
Publicado: (2012)

Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
por: Diebold, Matthias, et al.
Publicado: (2019)

Efficacy of ferric carboxymaltose in iron deficiency anemia patients scheduled for pancreaticoduodenectomy
por: Park, Jangho, et al.
Publicado: (2023)

The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial
por: Martens, Pieter, et al.
Publicado: (2021)

Evaluation of Minimal Optimal Dose of Intravenous Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia and Risk of Transient Hyperferritinemia
por: Alharbi, Ahmad A, et al.
Publicado: (2022)

Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020)

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
por: López‐Vilella, Raquel, et al.
Publicado: (2021)

Best precision in measuring Qp/Qs is achieved with quadratic, not linear, stationary tissue background correction in phase contrast velocity encoded CMR
por: Nickander, Jannike, et al.
Publicado: (2016)

Prevalence of increased myocardial extracellular volume fraction in dilated cardiomyopathy
por: Lundin, Magnus, et al.
Publicado: (2013)

Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials
por: Barish, Charles F., et al.
Publicado: (2012)

Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol
por: Schindler, Christoph, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7hlg8hp7bf68tvb5a5foljr40r